Federated Hermes Inc. increased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 1.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 127,752 shares of the biotechnology company’s stock after purchasing an additional 1,674 shares during the period. Federated Hermes Inc.’s holdings in Axon Enterprise were worth $33,002,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in AXON. American Century Companies Inc. increased its position in shares of Axon Enterprise by 103.8% during the first quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock valued at $853,000 after buying an additional 3,155 shares during the period. Private Advisor Group LLC grew its stake in Axon Enterprise by 40.3% during the first quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 994 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in Axon Enterprise by 12.3% during the 1st quarter. Great West Life Assurance Co. Can now owns 37,062 shares of the biotechnology company’s stock worth $5,247,000 after acquiring an additional 4,048 shares during the period. Raymond James Trust N.A. increased its holdings in Axon Enterprise by 4.7% during the 1st quarter. Raymond James Trust N.A. now owns 3,753 shares of the biotechnology company’s stock worth $517,000 after acquiring an additional 168 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Axon Enterprise by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 236,287 shares of the biotechnology company’s stock worth $32,545,000 after purchasing an additional 4,897 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.
Axon Enterprise Price Performance
AXON opened at $293.61 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. The stock’s 50 day simple moving average is $300.87 and its 200 day simple moving average is $258.44. The firm has a market cap of $22.16 billion, a price-to-earnings ratio of 127.65 and a beta of 0.93. Axon Enterprise, Inc. has a 1 year low of $175.37 and a 1 year high of $329.87.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.29. The firm had revenue of $432.14 million for the quarter, compared to analysts’ expectations of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. As a group, analysts predict that Axon Enterprise, Inc. will post 2.44 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on AXON. TheStreet downgraded Axon Enterprise from a “b” rating to a “c+” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. lifted their price target on Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research report on Thursday, April 11th. The Goldman Sachs Group boosted their price objective on Axon Enterprise from $297.00 to $339.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Needham & Company LLC raised their target price on shares of Axon Enterprise from $315.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Barclays boosted their price target on shares of Axon Enterprise from $296.00 to $308.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $312.64.
Check Out Our Latest Report on Axon Enterprise
Axon Enterprise Company Profile
(Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Articles
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.